H Lundbeck A/S
HLUN-A.CO · Health Technology · Pharmaceuticals: Major · DK
5,700 employees · lundbeck.com
About
H Lundbeck A/S, based in Valby, Denmark, is a pharmaceutical company specializing in brain disorder treatments. It develops, manufactures, and markets drugs for conditions including Alzheimer's, depression, Parkinson's, and schizophrenia, with key products like Cipralex, Ebixa, and Azilect. The company operates globally through subsidiaries such as Lundbeck SAS and Lundbeck GmbH, employing over 5,700 people.
Annual results
Reported figures, DKK · revenue up 10.7% in 2025
| Year | Revenue | Net income | Net margin | Free cash flow |
|---|---|---|---|---|
| 2025 | 24.4B | 3.2B | 13.1% | — |
| 2024 | 22.0B | 3.1B | 14.3% | — |
| 2023 | 19.9B | 2.3B | 11.5% | — |
| 2022 | 18.2B | 1.9B | 10.5% | — |
| 2021 | 16.3B | 1.3B | 8.1% | — |
Dividends per share
HLUN-A.CO in MarketPulse
The live chart with RSI and moving averages, the price, news, signals and price alerts for H Lundbeck A/S are inside MarketPulse — currently in private beta.
Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.